Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 288 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prevention of Sexually Transmitted Infections Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
Tenofovir, HEC Placebo, Open label tenofovir tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DCVax Plus Poly ICLC in Healthy Volunteers

NCT01127464
View directory record Official record
Conditions
HIV-1 Infection, HIV Infection, Healthy Volunteers
Interventions
DCVax-001, Poly-ICLC, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

NCT00002336
View directory record Official record
Conditions
Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
22
States / cities
Tucson, Arizona • Fresno, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 7, 2026, 12:20 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029
View directory record Official record
Conditions
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions
Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

NCT04804072
View directory record Official record
Conditions
HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder
Interventions
Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care, PrEP for participants without HIV, Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV), Testing and referral for treatment for hepatitis C virus (HCV), Sexually transmitted infection (STI) testing and treatment, Primary care, Harm reduction services, Peer navigation, COVID-19 testing and referral for further evaluation, care and/or treatment
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

NCT00002053
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 12:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services

NCT07292792
View directory record Official record
Conditions
HIV Disease, HIV Prevention
Interventions
Health Coach Intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

NCT00002074
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 12:20 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta

NCT07535346
View directory record Official record
Conditions
HIV Infections
Interventions
Health MPowerment App
Behavioral
Lead sponsor
Emory University
Other
Eligibility
14 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Feasibility and Preliminary Impact of a mHealth App on Reducing STI Risk in Black MSM PrEP Users

NCT05395754
View directory record Official record
Conditions
STI, Sexually Transmitted Diseases, Pre-exposure Prophylaxis
Interventions
App Intervention
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

NCT01327651
View directory record Official record
Conditions
HIV Infections
Interventions
Daily dosing, Time-driven dosing, Event-driven dosing
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Research in Ethno-Medicine and Education (REMED)

NCT05907187
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus, HPV, Human Papillomavirus Infection
Interventions
Cervical Cancer Prevention Education
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention

NCT03465852
View directory record Official record
Conditions
HIV Infections
Interventions
ChiCAS
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 2Phase 3 Interventional

Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR

NCT00164619
View directory record Official record
Conditions
Sexually Transmitted Diseases
Interventions
VOICES/VOCES, Standard STD clinic services
Behavioral · Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
3,660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques

NCT00252083
View directory record Official record
Conditions
HIV Infections
Interventions
Popular Opinion Leader
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention and Risk: Treatment With a New Emphasis on Relationships

NCT03396367
View directory record Official record
Conditions
Adherence, Medication, Risk Reduction, Drug Use, Sex, Anal, HIV/AIDS
Interventions
PARTNER, Education Intervention
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
View directory record Official record
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts

NCT00038688
View directory record Official record
Conditions
HIV Infections
Interventions
Peer HIV Education Program
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,610 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 4 Interventional

Fluconazole Prophylaxis of Thrush in AIDS

NCT00001542
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions
fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 2 Interventional

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

NCT00000643
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
24
States / cities
Palo Alto, California • Torrance, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

NCT05406583
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose), Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

NCT00187044
View directory record Official record
Conditions
HIV Infection, Human Immunodeficiency Virus
Interventions
PolyEnv1 vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Oct 7, 2026, 12:20 AM EDT